Oslo, Norway, and East Brunswick, NJ—NattoPharma has successfully secured patents in Canada and South Korea for its nature-identical synthesis creating MenaQ7 PharmaPure Vitamin K2 as MK-7, according to a press release.
- Canada: On May 25, 2021, patent #22,888,010 “Process for preparation of MK-7 type of Vitamin K2” was granted.
- South Korea: On March 15, 2021, Certificate of Patent #10-2229841 “Process for preparation of MK-7 type vitamin K2” was issued.
“This unique patented process results in the world’s only truly all-trans synthetic Vitamin K2 as MK-7,” said William Sommer, NattoPharma’s Vice President of Global Development & Regulatory, in the press release. “Our material is recognized as being of the highest quality, to which it is currently being utilized in multiple studies sponsored by the traditional medical community. This technology also ensures supplement manufacturers deliver the MK-7 with the health benefits customers desire.”
Related: Review Examines Link Between Vit K2 and Alzheimer’s
Nutrasource Announces Reception of Patent for IGEN Program
Study Uncovers How Nicotine Affects Calcification, Promotes Vit K2 as Possible Therapy
NattoPharma has made significant intellectual and monetary investments in technologies, according to the press release, and the company is committed to actively monitoring market developments to protect its intellectual property rights.
“The approval of these patents represents another milestone for NattoPharma and its partners,” offers Sophie Legrain-Raspaud, Global Research and Applications Director with Gnosis by Lesaffre, which owns NattoPharma. “This further strengthens our combined global IPR‐platform and improves our competitive position within the food supplement market. It is a wonderful development for NattoPharma and conveys the overwhelming promise of our recent merger.”